$3.92 3.9%
AMLX Stock Price vs. AI Score
Data gathered: October 17

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.


Amylyx Pharmaceuticals
Price $3.92
Target Price Sign up
Volume 3,310,000
Market Cap $268M
Year Range $1.62 - $19.57
Dividend Yield 0%
Analyst Rating 25% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '24-1M45M-46M-73M0-0.730
Q1 '2489M64M25M-119M-122M-0.120
Q4 '23108M62M47M4.7M2.2M0.070
Q3 '23103M54M49M21M19M0.300
Q2 '2398M49M49M22M20M0.310

Insider Transactions View All

Mazzariello Gina filed to sell 142,768 shares at $3.2.
October 2 '24
Bedrosian Camille L filed to sell 143,801 shares at $3.2.
October 2 '24
Cohen Joshua B filed to sell 3,220,569 shares at $3.2.
October 2 '24
Klee Justin B. filed to sell 3,120,569 shares at $3.2.
October 2 '24
FRATES JAMES M filed to buy 233,464 shares at $2.5.
September 16 '24

What is the Market Cap of Amylyx Pharmaceuticals?

The Market Cap of Amylyx Pharmaceuticals is $268M.

What is the current stock price of Amylyx Pharmaceuticals?

Currently, the price of one share of Amylyx Pharmaceuticals stock is $3.92.

How can I analyze the AMLX stock price chart for investment decisions?

The AMLX stock price chart above provides a comprehensive visual representation of Amylyx Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amylyx Pharmaceuticals shares. Our platform offers an up-to-date AMLX stock price chart, along with technical data analysis and alternative data insights.

Does AMLX offer dividends to its shareholders?

As of our latest update, Amylyx Pharmaceuticals (AMLX) does not offer dividends to its shareholders. Investors interested in Amylyx Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Amylyx Pharmaceuticals?

Some of the similar stocks of Amylyx Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.